A 28-week randomized controlled study by researchers in Japan, Canada and the United States finds that a 50% reduction of risperidone or olanzapine significantly improved cognitive function in patients with a schizophrenia diagnosis. The paper was published by Schizophrenia Bulletin.
Takeuchi, H., Suzuki, T, Remington, G., et al; Effects of risperidone and olanzapine dose reduction on cognitive function in stable patients with schizophrenia: An open-label, randomized, controlled, pilot study. Schizophrenia Bulletin, 39(5), 993-998. Online July 1, 2013. doi: 10.1093/schbul/sbt090